Press Releases
  Date Title and Summary View
Jul 13, 2009
ROCKVILLE, Md., July 13, 2009 /PRNewswire/ -- MacroGenics, Inc. today announced the initiation of the PARADIGM trial, a Phase 2 clinical study evaluating MGAWN1, a humanized monoclonal antibody, for the treatment of individuals with suspected central nervous system i...
Jun 23, 2009
ROCKVILLE, MD., June 23, 2009 /PRNewswire/ -- MacroGenics, Inc. announced today that Mr. Paulo F. Costa has been elected to the company’s Board as an independent director. Mr. Costa is the former President and Chief Executive Officer of Novartis U.S. Corporation. With more than 35 years of experience in operations and co...
Jun 16, 2009
ROCKVILLE, MD and INDIANAPOLIS, June 16, 2009 – MacroGenics, Inc. and Eli Lilly and Company (NYSE:LLY) today announced that the PROTÉGÉ trial achieved its targeted patient enrollment. The trial is a pivotal Phase 2/3 clinical study evaluating teplizumab, an investigational compound under development for the tre...
Mar 26, 2009
ROCKVILLE, Md., March 26 /PRNewswire/ -- MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced the appointment of Eric Risser as Vice President, Business Development.  "I am very pleased that we have been abl...
Sep 25, 2008
Rockville, Md.   September 25, 2008.  MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that it has raised $25 million in a Series D-2 financing.  The round, led by Nextech Venture...
Jul 17, 2008
Rockville, Maryland.  July 17, 2008.  MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced the acquisition of Raven Biotechnologies, Inc., a privately held biotechnology company in South San Francisco, Ca...
May 6, 2008
Rockville, Maryland.  May 6, 2008.  MacroGenics Inc, a private biotechnology company focused on the development of products to treat autoimmune disorders, cancers, and infectious diseases, today announced the appointments of Dr. Jean-Christophe Tellier as Executive Vice President and Chief Commercial Officer and Mr. Ja...
Oct 18, 2007
INDIANAPOLIS, IN and ROCKVILLE, MD – Eli Lilly and Company (NYSE:LLY) and MacroGenics, Inc. today announced that the two companies have entered into a global strategic alliance to develop and commercialize teplizumab, a humanized anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules ...
Sep 26, 2007
Rockville, MD.  September 26, 2007.  MacroGenics, Inc. announced today that Mr. Jeffrey H. Buchalter has been elected as Chairman of the company’s Board of Directors.  With more than 20 years of experience in product development and commercialization in the pharmaceutical and biotechnology industry, Mr. Buchal...
Aug 2, 2007
ROCKVILLE, MD. August 2, 2007. MacroGenics, Inc. announced today that its Protégé trial is actively enrolling adults and children ages 8 to 35 with recent-onset type 1 diabetes. The global Phase 2/3 clinical trial will evaluate the safety and efficacy of three teplizumab dosing regimens administered at the start of the...
Jul 9, 2007
ROCKVILLE, MD.  July 9, 2007.  MacroGenics announced today that the companys investigational new drug (IND) application to the U.S. Food and Drug Administration for its monoclonal antibody targeted to West Nile Virus is now active.  MGAWN1 is a humanized monoclonal antibody that specifically neutralizes the viru...
Jan 3, 2007
Rockville, MD. January 3, 2007. MacroGenics, Inc., a Maryland-based biotechnology company, and the Juvenile Diabetes Research Foundation (JDRF), the world's leading charitable funder of type 1 diabetes research, announced today that they have formed a partnership to support a pivotal multinational Phase II/III clinical trial of ...
Oct 16, 2006
Rockville, Maryland.  October 16, 2006.  MacroGenics, Inc., a privately-held immunotherapeutics company, announced today that John Maraganore, Ph.D., President and CEO of Alnylam Pharmaceuticals, has joined the MacroGenics Board of Directors.  With more than 20 years of opera...
Oct 10, 2006
Rockville, MD. October 10, 2006.  MacroGenics, Inc. announced today that its lead product candidate, MGA031, a humanized, Fc-engineered anti-CD3 monoclonal antibody, has received orphan drug designation from the Food and Drug Administration (FDA) for treatment of recent-onset type 1 diabete...
Oct 5, 2006
ROCKVILLE, MD.  October 5, 2006.  MacroGenics, Inc. today announced the publication of data showing that the companys humanized monoclonal antibody (Mab) targeted against CD32B demonstrated potent antitumor activity against B-cell lymphomas in preclinical studies. The Fcγ receptor, CD32B (FcγRIIB), is the pre...
Oct 2, 2006
Rockville, Maryland, October 2, 2006  MacroGenics, Inc. announced today that the National Institute for Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded the privately held biotechnology company a $50 million contract over five years to develop a monoclonal an...
May 17, 2006
Rockville, MD, May 17, 2006  MacroGenics, Inc., a privately-held biotechnology company developing therapeutics for autoimmune disorders, cancer, and infectious diseases, today announced that it has raised $45 million in a Series C financing round.  The financing, led by Ventures West, included new investment groups Cai...
Oct 19, 2005
ROCKVILLE, MD.  October 19th, 2005.  MacroGenics, Inc. today announced the grand opening of its recently completed cGMP manufacturing facility located in Rockville, Maryland. The Company celebrated the grand opening with over 70 invited guests, including members of the Maryland state government and Montgomery County governme...
Jul 18, 2005
ROCKVILLE, MARYLAND.  July 18, 2005.  MacroGenics, Inc. announced today the signing of an agreement with Tolerance Therapeutics, Inc. in which MacroGenics will acquire the intellectual property, materials, and know-how related to a promising anti-CD3 monoclonal antibody for the treatment of Type 1, or juvenile, diabetes and other autoi...
Jun 17, 2005
ROCKVILLE, MARYLAND.  June 17, 2005  MacroGenics, Inc. today announced the addition of R. Nelson Campbell and Ronald L. Wilder, M.D., Ph.D. to the companys senior management team, as well as the promotions of Ezio Bonvini, M.D. and Joseph Panigot.  Commenting on the recent additions, Dr. Scott Koenig, President and CEO of MacroGen...
Oct 19, 2004
For Immediate Release Rockville, MD, October 19, 2004  ROCKVILLE, Md., OCTOBER 19 -- OriGene Technologies Inc. and MacroGenics, Inc. announced today that the companies have entered into a license agreement for a cancer target initially identified with OriGene's HTP- Rapid-ScanTM technology. Macro...
Oct 15, 2004
For Immediate Release Rockville, MD, October 15, 2004  MacroGenics, Inc., a growing biotechnology company developing antibodies and vaccines to treat cancer, autoimmune disorders, and infectious diseases, announced the completion of its Series B financing of $30.5M led by Alta Partners and ...
Apr 26, 2004
CONTACTS: For Neose Technologies, Inc. Robert I. Kriebel - Sr. VP & CFO (215) 315-9000 Barbara Krauter - Manager (215) 315-9000 ...
Oct 29, 2003
CONTACTS: For Genzyme Sally Curley (investors) (617) 591-7140 Dan Quinn (media) (617) 591-5849 ...
Sep 4, 2003
The Department of Health and Human Services (HHS) today announced that the University of Texas Medical Branch at Galveston (UTMB) is among eight institutions nationwide receiving grants totaling approximately $350 million over five years to establish Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases Research (RCE). T...
Page: FirstPrevious ...
7
NextLast
= add release to Briefcase

Please note – you will leave a website owned by MacroGenics, Inc.

MacroGenics is not responsible for any content on the third party website.

Ok Close